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Accepted 29 October 2015Myoepithelial carcinoma (MC) is a rare tumor that arises from myoepithelial cells; most commonly in the
salivary glands, but other infrequent body sites such as the breast, lung, lower limb, upper limb, head and
neck, vulva, and vagina can be involved. We report the ﬁrst case of myoepithelial carcinoma arising in the
posterior mediastinum of a 51 year-old male who presented with a mediastinal mass and subsequently
underwent tumor debulking surgery. Grossly, the specimen consisted of multiple tan–gray ﬁrm fragments
of tissue with an overall measurement of 7.0 cm in greatest dimension. Histologic examination revealed
an ill-deﬁned, inﬁltrative lesion with a biphasic cell population. The tumor cells were diffusely positive
for epithelial and myoepithelial markers, conﬁrming the above diagnosis. Recognition of this entity at an
uncommon site may present a diagnostic challenge due to its morphologic heterogeneity and the differen-
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).2.1. Case report1. Introduction
Myoepithelial carcinoma (MC), the malignant counter part of
myoepithelioma, was ﬁrst described by Stromeyer et al. in 1975 [1]
and was included in the World Health Organization (WHO) classiﬁ-
cation of salivary gland neoplasms as a distinct clinicopathological
entity, in 1991 [2]. MC arises from myoepithelial cells and shows
both epithelial and smoothmuscle cell characteristics but lack ductal
differentiation [3]. They comprise less than 2% of all salivary gland
carcinomas, with the parotid gland being the most common site af-
fected [4]. However, uncommon localizations have been previously
reported such as the breast, palate, maxilla, nasophayrnx, liver,
vulva, and vagina [1,3,5–8]. Morphologic heterogeneity is a typical
histologic feature, with tumors displaying a mixture of different
cell types and growth patterns. The clinical behavior of MC tends to
be relatively aggressive, with a high rate of distant metastasis [9,10].540 East
BY-NC-ND liceTo the best of our knowledge, this is the ﬁrst case of primary
MC involving the posterior mediastinum. We describe the mor-
phologic and immunohistochemical ﬁndings and discuss the dif-
ferential diagnosis of this rare entity.2. Material and methodsA 51 year-old male presented to the Urology clinic complaining of
“bloody urine” for ﬁve months. As part of the workup, a computed
topographic scan (CT scan) of the abdomen and pelvis showed a sim-
ple renal cyst and an incidental left atrial mass measuring 5.0 cm in
greatest dimension (on higher CT cuts). Subsequently, CT scan of
the chest was performed which suggested a left atrial myxoma
(Fig. 1). At that time, the patient had no symptoms and was lost to
follow up. Five years later, he presented with shortness of breath
and palpitations. Electrocardiogram (EKG) revealed atrial ﬂutter.
Cardiac catheterization showed triple vessel coronary artery disease
and transesophageal echo (TEE) showed a signiﬁcant increase in thense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed Tomography of the chest showing heterogeneous non-enhancing mass extending superiorly to the inferior surface of the right main pulmonary artery.
24 E. Abdulfatah et al. / Human Pathology: Case Reports 5 (2016) 23–28size of the left intra-atrial mass which was 10.0 cm in the greatest di-
mension, compressing the superior vena cava and right main pulmo-
nary artery. Based on these ﬁndings, a decision was made to
perform coronary artery bypass graft (CABG) and tumor debulking
surgery.
Intraoperatively, the mass appeared to be mediastinal in origin
(rather than atrial), coursing behind the left atrium, posterior part
of the ascending aorta and involving the wall of the right and left
atrium.Table 1
















WT-1 DAKO/6 F-H22.2. Histology and Immunohistochemistry
Tissue sections were ﬁxed in 10% neutral buffered formalin, em-
bedded in parafﬁn, sectioned at 4-μm thickness, and stained with he-
matoxylin and eosin. The immunohistochemistry was performed
and evaluated at Wayne State University (Detroit Medical Center,
Detroit, MI), where the Ventana BenchMark Autostainer (Ventana
Medical System, Tucson, Arizona) was used on 4-μm thick
















Fig. 2. (A)Dual color break apart DNA probe showingnegative results for SS18 gene rearrangement. (B) The tumor consists of sheets and fascicles of spindle and epithelioid looking cells in
varying proportions within a hyalinized stroma (100×). (C) Clear and epithelioid looking cells with scant amount of eosinophilic cytoplasm and monotonous, hyperchromatic nuclei
(400×). (D) Closely packed fascicles of spindle cells with oval hyperchromatic nuclei (200×).
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(SMA), GFAP, WT1, calretinin, vimentin, caldesmon, CD99, bcl-2,
CD34, S-100 and desmin (Table 1).2.3. Cytogenetic studies
Tumor cellsweremicro-dissected from tissue block. Fluorescent in-situ
hybridization (FISH) analysis of the SS18 gene rearrangement was per-
formed at Detroit Medical Center University Laboratories (Detroit, MI)
using the LSI SS18/18q11.2 dual color break apart DNA probe (Vysis Inc.).3. Results3.1. Gross and microscopyGrossly, the specimen consisted of tan–gray, ﬁrm fragments of
tissue with an overall measurement of 7.0 × 7.0 × 3.0 cm. Histo-
logical examination revealed an ill-deﬁned inﬁltrative tumor,
with a biphasic cell population, spindle and epithelioid, in vary-
ing proportions, which blended with each other in a hyalinized
and occasionally myxoid stroma (Fig. 2B). The predominant spin-
dle cell areas consisted of solid sheets and fascicles of closely
spaced cells with scant amount of eosinophilic cytoplasm andmonotonous, hyperchromatic, ovoid nuclei (Fig. 2C-D). In other
areas, few pseudoglandular structures which consisted mainly
of epitheloid cells with eosinophilic cytoplasm and round nuclei
were identiﬁed. Nuclear atypia as well as mitosis was minimal
and no areas of necrosis were appreciated.3.2. Immunohistochemistry
Based on thesemorphologic features, the differential diagnosis of bi-
phasic tumors included synovial sarcoma, biphasic mesothelioma,
myoepithelial carcinoma, thymoma and malignant peripheral nerve
sheath tumor (MPNST). To further characterize the lesion, a panel of im-
munohistochemical stains was performed. The tumor cells were dif-
fusely positive for epithelial markers including AE1/AE3 and CK5/6
and myoepithelial markers including calponin, p63, smooth muscle
actin (SMA) and GFAP (Fig. 3). In addition, WT1, calretinin, vimentin,
caldesmon, CD99 (cytoplasmic), bcl-2, CD34, S-100 and desmin
immunostains were performed and were negative (Table 1).3.3. Cytogenetics studiesDue to the high clinical and morphological suspicion of synovial
sarcoma, ﬂuorescent in-situ hybridization (FISH) analysis of the
Fig. 3. Immunohistochemical staining of tumor cells showed diffuse positivity for (A) AE1/AE3, (B) CK5/6, (C) SMA, and (D) P63.
26 E. Abdulfatah et al. / Human Pathology: Case Reports 5 (2016) 23–28SS18 gene rearrangement was performed and was found to be nega-
tive, making this diagnosis less likely (Fig. 2).
Based on themorphology, imunophenotype and cytogenetic results,
the diagnosis of myoepithelial carcinoma/malignant myoepithelioma
was rendered. Due to the presence of residual tumor following surgery,
adjuvant radiation therapy was recommended. The patient passed
away four months later due to a subarachnoid hemorrhage, not related
to MC.4. DiscussionMyoepithelial tumors are rare and distinguishing benign from
malignant can be a major challenge. Although MC was described as an
entity more than 40 years ago [1], it remains under recognized, and its
diagnostic criteria as well as prognostic factors are still not
well delineated. Given its morphologic heterogeneity, MC may
be misdiagnosed, particularly when involving unusual sites.
For deﬁnitive diagnosis of this tumor, histopathological charac-
teristics and immunohistochemical proﬁle must be utilized to-
gether [8].
Histologically, the most characteristic feature of MC is its
multinodular architecture and its zonal cellular arrangement.
These tumors typically display solid, trabecular and/or reticularpatterns, with a variably prominent myxoid and/or hyalinized
stroma. The myxoid stroma is predominantly composed of chon-
droitin sulfate proteoglycans, while the eosinophilic hyaline com-
ponent represents basement membrane-related elements [11].
Additionally, different cell types including spindle shaped, epi-
thelioid, plasmacytoid and clear cells are often seen within the
same tumor. Focal luminal formations can be observed; however,
true ducts are almost never identiﬁed, which are required to de-
ﬁne epithelial–myoepithelial carcinoma. Various forms of meta-
plasia, including squamous, chondroid and sebaceous
differentiation may be seen, with squamous metaplasia being
the most common [12]. In our case, the tumor consisted of
solid sheets of spindle and epithelioid cells, present within a
hyalinized and occasionally myxoid stroma. Few pseudoglandular
structures were seen, but no true ducts were identiﬁed. More-
over, none of the previously reported metaplasia was noted.
Determination of myoepithelial differentiation on the sole
basis of morphology may be difﬁcult. In such cases, the use of
immunohistochemical stains might be helpful. Given that neo-
plastic myoepithelial cells may vary in their immunohistochemi-
cal protein expression proﬁles, the WHO has proposed that
reactivity for a cytokeratin and at least one of the myoepithelial
markers, including S100, SMA, calponin, GFAP and p63, is re-
quired to deﬁnitively diagnose MC [13]. Kane and Bagwan [14],
reported S100 positivity in the majority (95%) of their reported
series. Our case showed strong reactivity of the tumor cells
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calponin, p63, smooth muscle actin (SMA) and GFAP, thus fulﬁll-
ing the WHO criteria of a myoepithelial tumor. However, in
contrast to the previous studies, S100 was negative.
The histologic differential diagnosis of MC includes biphasic
tumors such as synovial sarcoma, biphasic mesothelioma, MPNST
and thymoma. Synovial sarcoma, particularly the biphasic form,
may show a marked resemblance to MC. The tumor consists of fasci-
cles of spindle cells admixed with numerous glandular structures
lined by cuboidal to columnar epithelium, set in a background of
variably collagenous stroma [15]. Immunohistochemically, in addition
to the positive staining in the epithelial component, the spindle cell
element shows at least focal positivity to EMA and cytokeratin.
CD99 shows membranous staining while bcl-2 shows cytoplasmic
staining in either or both components. Myoepithelial markers
are negative. Furthermore, 90% of synovial sarcomas show a
characteristic t(X;18)(p11.2;q11.2) [16]. While our case did exhibit
immunoreactivity to cytokeratin, bcl-2 and CD99 (cytoplasmic,
rather than membranous), the presence of strong expression of
more than one myoepithelial marker and the lack of characteristic
cytogenetic abnormality, made this diagnosis less likely.
Biphasic mesothelioma should also be considered in the dif-
ferential diagnosis of MC, particularly in the mediastinum.
These tumors present with a diffuse growth pattern usually in-
volving the visceral and parietal pleura and are characterized
by a combination of epithelioid and sarcomatoid elements in
varying proportions. Similar to MC, the tumor cells are positive
to cytokeratin (AE1/AE3) and CK5/6; however, they lack immu-
noreactivity to myoepithelial markers. In addition, speciﬁc
markers of mesothelial origin such as calretinin and WT1 are
expressed in the majority of mesotheliomas [17], which help in
differentiating them from MC.
Thymomas must be taken into account due to the mediastinal
origin of the tumor; however these tumors involve the anterior
rather than the posterior mediastinum. Microscopically these tu-
mors are generally encapsulated, with thick ﬁbrous septa divid-
ing them into lobules. Type A thymoma consists of fascicles of
spindle shaped epithelial cells with focal areas of glandular dif-
ferentiation, mimicking MC. In addition, scant amount of T cells
is present in the background [18]. Immunohistochemically, the
spindled epithelial cells stain positive for cytokeratin and EMA,
and the T-cell population exhibits a cortical thymocyte pheno-
type of TdT+, CD1a, and CD99 [19]. In our case, due to the in-
ﬁltrative growth pattern, posterior mediastinal involvement,
lack of co-existent lymphocytic component, and the characteristic
immunoproﬁle, thymoma was ruled out.
MPNST, the main differential diagnosis of synovial sarcoma,
shows epithelial (glandular) differentiation on rare occasions
and may require distinction from MC. These tumors typically
have a spindle-celled fascicular appearance and perivascular
whorling of tumor cells. Immunohistochemically, 50% of the
cases of MPNST are S-100 positive, whereas 20%–30% are GFAP
positive. Rare cases exhibit EMA positivity; however, none of
them show myoepithelial differentiation which is essential in
differentiating it from MC [20].
The clinical behavior of MC tends to be relatively aggressive.
In a recent study by Kong et al. [10], approximately one third
of the patients diagnosed with MC of salivary glands developed
distant metastasis, with lung being the most common site. A
major issue regarding MC has been the assessment of tumor
grading. Previous studies have shown no clear correlation
between different histologic features of MC and its clinical behav-
ior [14]. Savera et al. [12] classiﬁed MC as low grade when
the tumors displayed relatively uniform small sized nuclei and
as high grade when they showed marked cytologic atypia,
nuclear pleomorphism and high proliferative activity. Moreover,Kong et al. showed that the presence of tumor necrosis
correlated signiﬁcantly with a worse clinical behavior and there-
fore suggested deﬁning high grade MC on the basis of tumor ne-
crosis. Due to the rarity of MC, particularly in unusual sites,
the outcome and optimum management of these tumors
remain uncertain. Case studies have shown that chemotherapy
has a limited role and that surgical excision remains the main-
stay of treatment. Pertaining to our case, the tumor was consid-
ered unresectable. The patient underwent a suboptimal tumor
debulking surgery. Postoperative radiotherapy was initiated with
symptomatic improvement; however, the patient passed away
four months after surgery due to subarachnoid hemorrhage, not
related to MC.
In summary, we report the ﬁrst case of MC arising in the pos-
terior mediastinum. The morphologic heterogeneity of these tu-
mors requires supportive immunohistochemical stains to aid
diagnosis, especially for tumors in unusual sites. Greater aware-
ness of the occurrence of MC in the posterior mediastinum
may lead to increased recognition of this rare entity, with subse-
quent improved understanding of the optimum clinical manage-
ment and outcomes.References
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